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Abstract
Objective To quantitate the 2016 global and national
burden of chronic kidney disease (CKD) attributable to
ambient fine particulate matter air pollution ≤ 2.5 μm in
aerodynamic diameter (PM2.5).
Design We used the Global Burden of Disease (GBD) study
data and methodologies to estimate the 2016 burden of
CKD attributable to PM2.5 in 194 countries and territories.
Population-weighted PM2.5 levels and incident rates of CKD
for each country were curated from the GBD study publicly
available data sources.
Setting GBD global and national data on PM2.5 and CKD.
Participants 194 countries and territories.
Main outcome measures We estimated the attributable
burden of disease (ABD), years living with disability (YLD),
years of life lost (YLL) and disability-adjusted life-years
(DALYs).
Results The 2016 global burden of incident CKD attributable
to PM2.5 was 6 950 514 (95% uncertainty interval: 5
061 533–8 914 745). Global YLD, YLL and DALYs of CKD
attributable to PM2.5 were 2 849 311 (1 875 219–3 983 941),
8 587 735 (6 355 784–10 772 239) and 11 445 397 (8 380
246–14 554 091), respectively. Age-standardised ABD, YLL,
YLD and DALY rates varied substantially among geographies.
Populations in Mesoamerica, Northern Africa, several
countries in the Eastern Mediterranean region, Afghanistan,
Pakistan, India and several countries in Southeast Asia were
among those with highest age-standardised DALY rates. For
example, age-standardised DALYs per 100 000 were 543.35
(391.16–707.96) in El Salvador, 455.29 (332.51–577.97)
in Mexico, 408.41 (283.82–551.84) in Guatemala, 238.25
(173.90–303.98) in India and 178.26 (125.31–238.47) in Sri
Lanka, compared with 5.52 (0.82–11.48) in Sweden, 6.46
(0.00–14.49) in Australia and 12.13 (4.95–21.82) in Canada.
Frontier analyses showed that Mesoamerican countries had
significantly higher CKD DALY rates relative to other countries
with comparable sociodemographic development.
Conclusions Our results demonstrate that the global toll
of CKD attributable to ambient air pollution is significant
and identify several endemic geographies where air
pollution may be a significant driver of CKD burden. Air
pollution may need to be considered in the discussion of
the global epidemiology of CKD.
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Introduction
Several
studies
described
substantial
geographic variation in the burden of

Strengths and limitations of this study
►► The study leveraged the availability of the Global

Burden of Disease study data, which is the most
comprehensive compilation and analysis of global
health information available.
►► The study quantitated the burden of chronic kidney disease (CKD) attributable to air pollution using
the combined measure of disability-adjusted lifeyears, which comprehensively captures the years of
healthy life lost due to dying prematurely and to the
years living with disability.
►► For each estimate reported in this study, we also
provide a measure of uncertainty (uncertainty intervals) to reflect how much is known, but more importantly how much is not known.
►► The burden was quantitated at the country level; the
study does not provide subnational estimates of CKD
burden.
►► Global burden of disease estimates, while considered robust and reliable, are necessarily limited by
the quality of the available data.

chronic kidney disease (CKD) that cannot
be explained by traditional drivers including
diabetes and hypertension.1–4 It was
suggested that other risk factors including
environmental pollution may explain these
geographic variations.5 We recently characterised fine particulate matter of <2.5 µm in
aerodynamic diameter (PM2.5) as a novel risk
factor for development and progression of
kidney disease and described a linear relationship between exposure to levels of PM2.5
and risk of incident CKD, kidney disease
progression and end-stage renal disease.6
The global burden of kidney disease attributable to ambient air pollution has not been
previously described. A quantitative assessment of the global burden of kidney disease
attributable to air pollution might explain
some of the geographic variation in burden
of kidney disease, help identify endemic areas
and contribute to the global and national
discussions about the effect of environmental
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Methods
Global data sources
National PM2.5 exposure levels were obtained from
publicly available 2016 GBD data.7–9 The GBD PM2.5 values
are derived from the integration of satellite data, surface
measurements, geographic data and a chemical transport
model at a 1° (approximately 11 by 11 km at the equator)
resolution, and then aggregated to national-level population-weighted means to produce a national exposure
estimate.7 8 Estimates of global and national incident
rates, YLDs, YLLs, DALYs of CKD and their uncertainty
levels were obtained from the publicly available 2016
GBD.10 11 The GBD aims to use all accessible information
on disease occurrence, natural history and severity that
meets inclusion criteria, drawing on a large network of
collaborators for subject matter expertise on disease and
injury to generate internally consistent, comprehensive
global health statistics on the burden of disease.12 GBD
uses an integrative Bayesian meta-regression method
that estimates a generalised negative binomial model
for all epidemiological data through DisMod-MR 2.1 to
compute GBD estimates of disease burden including
YLDs, YLLs and DALYs.12 Estimates are generated using
hierarchical modelling methodology that accounts for
temporal, geospatial, sex, age and cause specific variance
to establish attributable burden of disease across all levels
of the GBD framework.10 13–16 Key to GBD estimates are
the propagation of uncertainty through the modelling
process, which incorporates uncertainty due to diversity
in data sources, sparsity of data for some parts of the
world, modelling choices and other factors that impact
estimation such as the determination of disability weights.
Detailed descriptions of overall GBD 2016 methodologies
and specific CKD methodology have been provided elsewhere.10 12–17 Population size was obtained from the GBD
Population Estimates dataset.18 Country income classifications were obtained from the World Bank.19
PM2.5 risk estimation
PM2.5 risk estimation was obtained from prior work
assessing the association of PM2.5 with kidney disease
outcomes.6 Department of Veterans Affairs datasets were
linked with the Centers for Disease Control and Prevention’s National Environmental Public Health Tracking
Network annual particulate matter estimates for the
contiguous USA, which originates from Community Multiscale Air Quality modelled output.20 Time-dependent
2

adjusted Cox proportional hazard survival models, where
cohort participants’ exposure was updated annually and
on movement in residence, were used to investigate
the association between PM2.5 and time until incident
estimated glomerular filtration rate (eGFR) <60 mL/
min/1.73 m2. Models were adjusted for age, race, sex,
cancer, cardiovascular disease, chronic lung disease,
diabetes mellitus, hyperlipidaemia, hypertension, eGFR
at time of cohort entry, body mass index, smoking status,
ACE inhibitor/angiotensin receptor blocker use, county
population density, number of outpatient eGFR measurements, number of hospitalisations and county percent in
poverty. Restricted cubic spline analyses of PM2.5 suggested
no deviation from linearity in the range of PM2.5 in the
study (5.0–22.1 µg/m3). Alternate analyses using time
zero exposure values and using National Aeronautics and
Space Administration (NASA) data as an alternate exposure source produced consistent results.21 22 Ambient
sodium levels were investigated as a negative control,
where there existed no biological bases to support an
association with risk of incident CKD. Results for every
IQR (the distance between the 25th and 75th percentile; 0.046 µg/m3) increase in sodium showed a vanishingly weak association, 0.99 (0.99–0.99). Results were
consistent in sensitivity analyses that used ground-level
measures only and that assessed potential confounding
by shared regional characteristics.6 To estimate risk in
each country, we relied on the PM2.5 pollution and risk
relationship characterised in the prior study described
above6 where PM2.5 levels ranged from 5.0 to 22.1 µg/m3.6
In this study, we took a conservative approach where we
considered annual average PM2.5 exposure greater than
22.1 µg/m3 to contribute the same amount of risk as an
exposure of 22.1 µg/m3.7 23 This approach is supported
by findings from GBD and several other studies where
integrated exposure response functions suggest that risk
of adverse health outcomes of PM2.5 pollution levels off
(follows a near plateau morphology) at PM2.5 concentrations exceeding 20–25 µg/m3.7 8 23
Population attributable fraction and ABD
The population attributable fraction (PAF) of CKD due
to PM2.5 exposure above the theoretical minimum risk
exposure level (TMREL) was calculated using an adapted
GBD equation.14 This PAF can be interpreted as the
proportion of incident CKD attributable to PM2.5 exposure that exceeds the TMREL. The proportional hazardsbased equation for PAF in a country is:
( )
(
)
HR x −HR TMREL
( )

HR x


PAF =

where HR(x) is the HR for PM2.5 at the national exposure level, and HR(TMREL) is the HR for PM2.5 at the
TMREL. The TMREL was defined according to the GBD
study methodologies.8 23 24 The TMREL was assigned as a
uniform distribution of PM2.5 from 2.4 µg/m3to 5.9 µg/
m3, which represents exposure values between the
minimum and fifth percentiles of exposure distributions
Bowe B, et al. BMJ Open 2019;9:e022450. doi:10.1136/bmjopen-2018-022450
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pollution on non-communicable disease in general and,
more specifically, on the potential impact of air pollution
on the global epidemiology of CKD. In this work, we used
the Global Burden of Disease (GBD) study methodologies
to estimate the burden of CKD attributable to fine particulate matter air pollution in 194 countries and territories using the following measures: attributable burden of
disease (ABD), years living with disability (YLD), years of
life lost (YLL) and disability-adjusted life-years (DALYs).

Open access

ABD = PAF ∗ IR ∗ population 

where PAF is the population attributable fraction, IR
is the incident rate of CKD, and population is the size of
the population of the country or territory in which the
burden is being assessed.2 Results were repeated using
the WHO TMREL.
YLD, YLL and DALYs
YLD, YLL and DALY values were estimated by multiplying the CKD-specific GBD values of the corresponding
burden measure by the PAF,13 17 resulting in YLD, YLL
and DALY values due to CKD attributable to PM2.5. YLD,
YLL and DALY estimates due to CKD were obtained from
the GBD results tool.10 11 The basis of their calculation is
presented below; further information has been described
elsewhere.13 17 Results were repeated using the WHO
TMREL.
YLD due to CKD is calculated as:
Y LD = P ∗ DW 

where P is the prevalent cases of CKD in the population,
and DW is the disability weight for CKD representative of
the severity of its impact on a person’s life (0: no impact,
to 1: the same as death). YLD due to CKD is a measure of
the burden placed on a population due to the ill effects
of living with CKD.26
YLL due to CKD is calculated using the equation:
Y LL = N ∗ L 

where N is the number of deaths due to CKD and L is the
difference between age of death and average life expectancy due to CKD. YLL due to CKD is a measure of the
burden placed on a population due to dying prematurely
from CKD. Estimates of the difference between average
life expectancy and age of death from CKD come from a
GBD set of age and location–year specific life tables.10 13–16
DALYs due to CKD is calculated using the equation:
	

DALY = YLD + YLL 

The DALY due to CKD is a summary measure of YLD
and YLL and represents the total years of healthy life lost
due to ill health, disability or early death due to CKD.
Measure estimation and uncertainty
In order to incorporate the uncertainty in measurements
used in our estimation, all measures were generated from
a distribution of 10 000 predictions, where the median
(uncertainty interval (UI): 2.5th–97.5th percentile)
Bowe B, et al. BMJ Open 2019;9:e022450. doi:10.1136/bmjopen-2018-022450

are reported. Predictions incorporated uncertainty
by randomly sampling from, unless otherwise specified, constructed normal distributions of the relevant
measures. Uncertainty was derived from the TMREL
distribution, the SE of the PM2.5 beta estimate and the
uncertainty of the incident rates, YLD, YLL and DALY
from the GBD data. While accounting for variability in
measures, measures sampled under 0 were set to 0. Values
of 0 thus represent instances of estimated zero burden,
reflective of areas where the corresponding PM2.5 levels
are below the TMREL distribution or where uncertainty
was enough to result in such estimates. Maps of age-standardised rates are presented. All analyses were performed
in SAS Enterprise Guide V.7.1. Maps were generated
using Arc Map 10 (ESRI, Redlands, California, USA). The
circular layout image was generated using the Circos software package.27
Frontier analysis
Frontier analysis was conducted as a quantitative methodology to identify the lowest potentially achievable
age-standardised DALYs on the basis of development
status as measured by the Sociodemographic Index
(SDI). SDI is a summary measure of a country or territory’s sociodemographic development; it is a composite
measure of average income per person, educational
attainment and total fertility rate in any given country.
The minimum possible SDI is 0, while the maximum is
100; it is comparable across geography and over time.28
The DALYs frontier delineates the minimum DALY that
could be achieved for every geography (country or territory) given its SDI. Distance from the frontier is termed
effective difference; if a country or territory exhibits a
large effective difference from the frontier given its SDI,
then this likely suggests unrealised opportunities for gains
or improvement (reduction in DALYs) that should be
possible based on the country or territory’s state on the
development spectrum. A data envelope analysis, which
allows for non-linear frontiers, using the free disposal
hull method was developed to produce a frontier for age
adjusted DALYs.28 29 In order to account for uncertainty,
we used 1000 bootstrapped samples of the data, randomly
sampling with replacement from all countries and territories. LOESS regression was then used on this result to
produce a smoothed frontier.28 Super-efficient countries
were excluded, to remove the influence of outliers, in the
generation of the frontier.28 Absolute distances from the
frontier of each country are reported as effective difference, where any countries with lower DALYs than the
frontier were assigned a 0 distance.
In order to account for the effect of variation in
prevalence of primary drivers of CKD (hypertension
and diabetes) on differences in overall DALY rates, we
repeated the frontier analysis following a decomposition
analysis to generate risk deleted cause-specific age-standardised DALY rates of CKD attributable to PM2.5,17 where
risks deleted were hypertension and diabetes. Diabetes
and hypertension cause-specific CKD rates were obtained
3
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from outdoor air pollution cohort studies included in the
GBD anlayses.8 23 24 Levels under the TMREL were treated
as contributing no risk.8 Results were repeated using the
WHO Air Quality Guidelines for annual average of PM2.5
concentration of 10 µg/m3 as the TMREL.25
Burden of CKD attributable to PM2.5 above the TMREL,
as the number of incident CKD per year attributable to
PM2.5 above the TMREL, was calculated using estimates
from the 2016 GBD,13 from the equation:

Open access

Country

PM2.5 (μ g/m3)

ABD (in 1000s)

ABD (per 100 000)

Age-standardised
ABD (per 100 000)

Global

42.27

China

57.2

6950.51
(5061.53–8914.74)
766.73
(558.72–985.14)

94.29
(68.67–120.94)
55.42
(40.39–71.21)

101.39
(74.49–129.69)
48.98
(35.52–63.01)

India

72.6

1092.52
(791.38–1407.28)

83.30
(60.34–107.29)

108.21
(77.99–139.22)

US

8.3

163.49
(88.76–262.78)

50.53
(27.44–81.22)

35.44
(19.39–57.44)

Indonesia

15.0

76.81
(53.66–103.42)

29.81
(20.83–40.15)

37.38
(26.05–50.06)

Brazil

11.1

69.03
(45.11–99.44)

33.21
(21.70–47.84)

36.57
(23.68–52.72)

Pakistan

63.0

107.43
(78.85–137.04)

56.83
(41.71–72.49)

89.17
(64.66–114.14)

Nigeria

36.9

195.23
(141.44–250.95)

106.98
(77.51–137.52)

200.28
(145.24–261.20)

Bangladesh

87.0

136.17
(99.56–174.46)

84.60
(61.86–108.39)

121.08
(88.55–156.18)

Russia

15.8

Japan

13.1

170.89
(118.90–229.76)
134.56
(91.13–186.81)

115.38
(80.27–155.12)
104.88
(71.03–145.60)

82.87
(57.99–111.67)
44.79
(30.61–61.70)

PM2.5, fine particulate matter <2.5 µm.

from the 2016 GBD, which were then subtracted from
overall rates and then multiplied by the PAF.11 The risk
deleted DALY can be conceptualised by the formula:
)
(
DALYO = DALYDHO ∗ 1 − PAFDH 
where DALYO is the DALY due to other causes, DALYDHO
is the DALY due to all three causes and PAFDH is the
population attributable fraction due to diabetes and
hypertension.
Patient involvement
No patients were involved in developing the aims, design
or implementation of this study. No patients were involved
in the interpretation of study results, or write up of the
manuscript.
Results
Global burden of kidney disease attributable to air pollution
In 2016, the global annual burden of incident CKD
attributable to elevated PM2.5 was, in 1000s, 6950.51 (95%
uncertainty interval: 5061.53–8914.74). ABD rate per
100 000 people was 94.29 (68.67–120.94), and age-standardised ABD rate per 100 000 was 101.39 (74.49–129.69)
(table 1).
The 2016 global YLD, YLL and DALYs of CKD attributable to elevated PM2.5 are reported in table 2 as absolute
4

values in 1000s, rates per 100 000 population and age-standardised rates per 100 000. Age-standardised rates for
YLD, YLL and DALYs were 40.97 (26.84–57.11), 122.71
(90.36–153.52) and 163.69 (120.58–207.28), respectively
(table 2).
Burden of kidney disease attributable to air pollution at the
national level
ABD, YLD, YLL and DALYs reported as absolute values,
as rates per 100 000 population and as age-standardised
rates per 100 000 population for 10 most populated countries (tables 1 and 2) and for 194 countries and territories
are provided in online supplementary table 1 and online
supplementary table 2.
Among the 10 most populated countries in the world,
India followed by China had the highest attributable burden
of incident CKD due to air pollution globally (ABD=10 92.52,
UI=791.38–1407.28, and 766.73, 558.72–985.14, in 1000s,
respectively). India also outranked China in estimates standardised by population size and age distribution (table 1).
Age-standardised ABD in the 10 most populated countries
showed Nigeria, Bangladesh and India having high burden
exceeding 100 incident cases of CKD per 100 000 population (table 1). Age-standardised ABD per 100 000 population
varied substantially among geographies, where it was highest
in Guinea-Bissau, El Salvador, Senegal, Togo, Benin, Mauritania, Chad, Ghana, Niger and Mali (online supplementary
Bowe B, et al. BMJ Open 2019;9:e022450. doi:10.1136/bmjopen-2018-022450
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Table 1 Attributable burden of chronic kidney disease (ABD) associated with PM2.5 exposure globally and for the top 10 most
populous countries

447.47 (289.00–
638.28)

61.54 (32.36–
105.07)

40.67 (25.55–60.13) 15.79 (9.92–
23.34)

25.72 (15.29–39.59) 12.38 (7.36–
19.05)

47.74 (30.60–68.12) 25.25 (16.19–
36.03)

61.22 (38.09–88.68) 33.55 (20.87–
48.59)

51.45 (33.04–72.84) 31.96 (20.53–
45.25)

45.31 (27.94–67.45) 30.59 (18.86–
45.54)

57.64 (36.80–84.54) 44.92 (28.68–
65.89)

India

US

Indonesia

Brazil

Pakistan

Nigeria

Bangladesh

Russia

Japan
21.97 (13.83–
32.50)

22.99 (14.08–
34.08)

45.58 (28.89–
64.56)

71.93 (45.61–
103.27)

39.99 (25.77–
56.99)

13.55 (8.11–
20.94)

20.02 (12.80–
29.32)

14.51 (7.59–
24.72)

45.40 (29.19–
64.54)

29.12 (19.36–
41.01)

40.97 (26.84–
57.11)

72.08 (49.89–
97.36)

54.05 (32.23–
81.33)

168.36 (121.18–
220.47)

57.66 (37.92–
80.13)

292.68 (174.43–
434.38)

98.88 (65.54–
139.27)

224.57 (158.94–
297.66)

104.78 (58.14–
165.08)

2048.91(1471.02–
2662.61)

1188.22 (870.96–
1501.83)

8587.74(6355.78–
10 772.24)

YLL
(in 1000s)

56.18 (38.88–
75.88)

36.49 (21.76–
54.91)

104.60 (75.28–
136.98)

31.60 (20.78–
43.91)

154.81 (92.27–
229.76)

47.57 (31.53–
67.01)

87.17 (61.70–
115.54)

32.39 (17.97–
51.03)

156.21 (112.15–
203.00)

85.89 (62.95–
108.56)

116.51 (86.23–
146.14)

YLL
(per 100 000)
11 445.40 (8380.25–
14 554.09)

DALYs
(in 1000s)

2502.15(1827.96–
3204.77)

265.23 (186.14–
351.41)

342.45 (213.87–
492.17)

220.26 (159.56–
283.60)

23.15 (16.00–31.22) 129.79 (88.75–
178.70)

28.25 (16.88–42.28) 100.14 (66.26–
140.14)

137.57 (98.14–
179.69)

44.94 (29.23–62.98) 119.40 (82.97–
161.55)

215.59 (123.95–
322.52)

51.17 (34.05–72.01) 124.85 (82.57–
176.65)

102.00 (72.07–
134.72)

23.30 (12.96–36.77) 166.61 (91.84–
264.98)

192.55 (138.73–
249.04)

76.18 (55.93–96.49) 1651.72 (1212.35–
2103.21)

122.71 (90.36–
153.52)

Agestandardised YLL
(per 100 000)

163.69 (120.58–
207.28)

Age-standardised
DALYs
(per 100 000)

37.92 (20.91–60.47)

238.25 (173.90–
303.98)

117.66 (81.05–
158.12)

254.25 (157.33–
365.23)

64.76 (42.92–91.88)

51.29 (34.08–72.60)
101.16 (69.17– 45.26 (30.63–62.55)
139.27)

67.61 (44.74–
94.61)

136.84 (99.13– 183.21 (132.76–
176.20)
236.87)

65.43 (45.47–
88.52)

181.14
(113.12–
260.33)

60.07 (39.72–
84.99)

102.95 (72.25– 122.19 (86.18–
136.41)
162.36)

51.50 (28.39–
81.90)

190.77
(139.37–
244.33)

119.39 (87.63– 105.79 (77.30–
152.02)
133.98)

155.27
(113.69–
197.45)

DALYs
(per 100 000)
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19.02 (10.00–
32.48)

34.12 (22.03–
48.66)

33.41 (22.01–
46.79)

462.21 (304.57–
647.27)

China

38.66 (25.44–
54.05)

2849.31(1875.22–
3983.94)

YLD (per
100 000)

Global

Country

YLD
(in 1000s)

Agestandardised
YLD (per
100 000)

Table 2 Years living with disability (YLD), years of life lost (YLL) and disability-adjusted life-years (DALYs) of chronic kidney disease associated with PM2.5 for the top 10
most populous countries
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table 1 , figure 1). Mapping the geographic distribution of
age-standardised ABD rates showed high burden in Mesoamerica, several countries in Central and South Africa,
Mongolia and several countries in the Far East and the
Eastern Mediterranean region (figure 1). Countries with
the lowest age-standardised ABD per 100 000 population
included Canada, Greenland, several countries in Scandinavia, Brunei, New Zealand and Australia (online supplementary table 1 , figure 1).
Years living with disability
Estimates for YLD in absolute terms, rates per 100 000
population and age-standardised YLL rates are provided in
table 2 for the 10 most populated countries and in online
supplementary table 2 for 194 countries and territories.
Among the 10 most populated countries, Nigeria had the
highest age-standardised YLD rate per 100 000 population
(YLD=71.93, UI=45.61–103.27), followed by Bangladesh
(45.58, 28.89–64.56) and then India (45.40, 29.19–64.54).
Among all countries, Iraq, Afghanistan, Guinea-Bissau,
Senegal, Chad, Turkey, Mali, Niger and Yemen had the
highest age-standardised YLD rate per 100 000 population
(online supplementary table 2 , figure 2).
Years of life lost
Estimates for YLL in absolute numbers, rates per 100 000
population and age-standardised rates per 100 000 population for 10 most populated countries and for 194 countries
and territories are provided in table 2 and online supplementary table 2, respectively. Among the 10 most populated countries, Pakistan had the highest age-standardised
YLL per 100 000 population (YLL=215.59, UI=123.95–
322.52), followed by India (192.55, 138.73–249.04) and
6

then Bangladesh (137.57, 98.14–179.69). Among all countries and territories, Afghanistan, El Salvador, Nicaragua,
Mexico, Honduras, Philippines, Guatemala, Iraq, Palestine
and Belize had the highest age-standardised YLL per 100 000
population (online supplementary table 2 , figure 3).
Disability-adjusted life-years
Among the 10 most populated countries, India had the
highest DALY (DALY=2502.15, UI=1827.96–3204.77 in
1000s), followed by China (1651.72, 1212.35–2103.21) and
then Pakistan (342.45, 213.87–492.17) (table 2). DALY rates
per 100 000 population showed that India remained on top
with DALY rate of 190.77 (UI=139.37–244.33), followed
by Pakistan with DALY rate of 181.14 (UI=113.12–260.33),
then Bangladesh with DALY rate of 136.84 (UI=99.13–
176.20) (table 2). Age-standardised DALY rates showed
Pakistan leading, followed by India, then Bangladesh with
age adjusted DALY rates of 254.25 (UI=157.33–365.23),
238.25 (UI=173.90–303.98) and 183.21 (132.76–236.87),
respectively.
Among all countries and territories, those with the highest
age-standardised DALY rates included Afghanistan, El
Salvador, Nicaragua, Mexico, Honduras, Iraq, Guatemala,
Philippines, Palestine and Belize (online supplementary table
2). Mapping the geographic distribution of age-standardised
DALY rates across the globe showed populations in Mesoamerica, Northern Africa, South Africa, several countries in
the Eastern Mediterranean Region, Afghanistan, Pakistan,
India and several countries in Southeast Asia were among
those with highest age-standardised DALY rates (figure 4). For
example, age-standardised DALYs per 100 000 were 543.35
(391.16–707.96) in El Salvador, 455.29 (332.51–577.97)
Bowe B, et al. BMJ Open 2019;9:e022450. doi:10.1136/bmjopen-2018-022450
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Figure 1 Age-standardised burden (ABD) of incident chronic kidney disease attributable to PM2.5 per 100 000 population. ATG,
Antigua and Barbuda; FSM, Federated States of Micronesia; Isl, island; LCA, Saint Lucia; PM2.5, fine particulate matter <2.5 µm;
TLS, Timor-Leste; TTO, Trinidad and Tobago; VCT, Saint Vincent and the Grenadines.
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in Mexico, 408.41 (283.82–551.84) in Guatemala, 295.39
(203.17–401.39) in Jordan, 273.55 (184.84–379.35) in Egypt,
264.23 (181.58–360.76) in Morocco, 259.46 (189.72–330.98)
in South Africa, 205.12 (148.73–264.89) in Thailand, 183.21
(132.76–236.87) in Bangladesh and 178.26 (125.31–238.47)
in Sri Lanka. The map identified Canada, several northern
European and Scandinavian countries, New Zealand and
Australia as having lowest estimates of age-standardised

DALY rates. For example, age-standardised DALY rates were
5.52 (0.82–11.48) in Sweden, 6.46 (0.00–14.49) in Australia,
and 12.13 (4.95–21.82) in Canada (figure 4).
Frontier analysis
We developed a frontier analysis to identify countries and
territories that exhibited the least burden of kidney disease
attributable to particulate matter air pollution given their

Figure 3 Age-standardised years of life lost (YLL) due to incident chronic kidney disease attributable to PM2.5 per 100 000
population. ATG, Antigua and Barbuda; FSM, Federated States of Micronesia; Isl, island; LCA, Saint Lucia; PM2.5, fine particulate
matter <2.5 µm; TLS, Timor-Leste; TTO, Trinidad and Tobago; VCT, Saint Vincent and the Grenadines.
Bowe B, et al. BMJ Open 2019;9:e022450. doi:10.1136/bmjopen-2018-022450
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Figure 2 Age-standardised years living with disability (YLD) due to incident chronic kidney disease attributable to PM2.5 per
100 000 population. ATG, Antigua and Barbuda; FSM, Federated States of Micronesia; Isl, island; LCA, Saint Lucia; PM2.5, fine
particulate matter <2.5 µm; TLS, Timor-Leste; TTO, Trinidad and Tobago; VCT, Saint Vincent and the Grenadines.

Open access

SDI. The analysis provides a comparative quantitative assessment of the potential reduction in CKD burden that might be
achievable in each country given their social and economic
development. Most importantly, for each SDI, this analysis
identifies exemplar countries at the frontier (with lowest
DALYs for their SDI) and countries with the highest DALYs
for their SDI. The effective difference between the frontier
and the highest DALYs given an SDI represents a hypothetical magnitude of potential improvement in impact of air
pollution on burden of CKD in a given country. Frontier analysis of age-adjusted DALYs are presented in figure 5. Online
supplementary table 3 provides the effective difference from
the frontier for each country given that country SDI; countries with the largest effective difference were El Salvador,
Afghanistan, Mexico, Nicaragua, Honduras, Philippines,
Iraq, Guatemala and Palestine. Among countries with an
SDI <0.3, Somalia, Niger, Liberia, the Democratic Republic
of Congo, Mozambique and Burundi had age-standardised
DALY rates that are close to the frontier with an effective
difference of less than 10. Afghanistan, Guinea-Bissau and
Chad also had an SDI <0.3; however, they exhibited relatively
high age-standardised DALY rates and effective difference
from the frontier that exceeded 100 representing a large
gap in performance vis-à-vis other countries with comparable resources. Among reasonably well-resourced countries
with an SDI >0.7, Mexico, Mauritius, The United Arab Emirates, Saudi Arabia, Turkmenistan, Venezuela, South Africa,
Bahrain and Mongolia had an effective difference from the
frontier of more than 200 representing potential unrealised
opportunities for progress in those countries given their
resources.
To further evaluate the frontier independent of potential contamination by other strong drivers of CKD such as
8

diabetes—where it is a major driver in Mexico30—and hypertension, we rebuilt the entire frontier following a decomposition analysis of risk-deleted cause-specific DALYs where we
risk-deleted DALYs caused by diabetes and hypertension.
This analysis yielded consistent results (online supplementary figure 1); specifically, that several countries including
Mesoamerica exhibited significant effective difference from
the frontier suggesting a disproportionally higher PM2.5
attributable DALYs than would be expected by their SDI
(online supplementary figure 1).
Burden of CKD attributable to PM2.5 levels above the WHO limit
of 10 µg/m3
All the primary analyses were developed considering risk
attributable to exposure levels of PM2.5 above a uniform
distribution between 2.4 µg/m3and 5.9 µg/m3 representing
exposure values between the minimum and fifth percentiles of exposure distributions from outdoor air pollution
studies.7 8
We repeated all the analyses where we considered risk
attributable to exposure levels of PM2.5 above the WHO limit
of 10 µg/m3 (using the alternate scenario where the theoretical minimal risk exposure level was set at 10 µg/m3).6
The estimates describe the burden of kidney disease—globally and at the national level—that is attributable to PM2.5
concentrations in excess of the WHO limit. The geographic
distribution of burden was consistent with the primary
results (online supplementary tables 4 and 5). The results
from this analysis necessarily underestimate the true burden
as they—by definition—ignore PM2.5-related risk below the
WHO limit but might be informative to policy makers and
relevant stakeholders in estimating the burden of CKD that
Bowe B, et al. BMJ Open 2019;9:e022450. doi:10.1136/bmjopen-2018-022450
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Figure 4 Age-standardised disability-adjust life-years (DALYs) due to incident chronic kidney disease attributable to PM2.5 per
100 000 population. ATG, Antigua and Barbuda; FSM, Federated States of Micronesia; Isl, island; LCA, Saint Lucia; PM2.5, fine
particulate matter <2.5 µm; TLS, Timor-Leste; TTO, Trinidad and Tobago; VCT, Saint Vincent and the Grenadines.
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could be avoided should targeting the WHO limit become a
policy goal.
Discussion
In this work, we provide a quantitative analysis of the
global burden of CKD attributable to air pollution in 194
countries and territories. The results describe the annual
incidence of kidney disease attributable to air pollution
globally and at the national level and provide a quantitative assessment of the YLD due to kidney disease, YLL due
to early mortality from kidney disease and the combined
comprehensive measure of DALYs (years of healthy life
lost, due to dying prematurely and and to the YLD) of
kidney disease attributable to air pollution. The global
toll of CKD attributable to air pollution is significant with
6.9 million incident cases of CKD per year, 94 cases per
100 000 population per year and 11.4 million DALYs per
year. The findings suggest substantial geographic variation
and identify geographies where the toll of air pollution
may be a significant driver of the epidemiology of kidney
disease. Our analyses also suggest disproportionately
Bowe B, et al. BMJ Open 2019;9:e022450. doi:10.1136/bmjopen-2018-022450

higher PM2.5 DALYs from kidney disease in several countries including Mesoamerica than would be expected for
their SDI.
According to the GBD study, global age-standardised
DALY rates attributable to PM2.5 are 1521 per 100 000.31
Our estimates of PM2.5 CKD DALYs were 164, representing
10.7% of the total global DALYs—years of healthy life
lost—attributable to air pollution.31 Our analyses suggest
that the overall burden of kidney disease attributable to
air pollution is shaped by the epidemiological transition.32
Among countries that are poor with a high burden of
communicable diseases and reduced life expectancy (eg,
several countries in the African continent), we observed
a lower global ranking for YLL  than YLD (figures 2 and
3), reflecting increased probability of early loss of life
from other diseases not related to air pollution. The
corollary observation is that countries that are relatively
more developed including Mesoamerica, South America
(including Venezuela, Gynae, Surinam and Bolivia), Pakistan, India and several countries in southeast Asia ranked
in the highest decile for YLL but not in YLD, reflecting
9
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Figure 5 Frontier analysis of age-standardised disability-adjusted life-years (DALYs) rate per 100 000 population by
Sociodemographic Index. Countries with the top 10% effective difference are labelled. Countries are coloured by region.
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Our results show substantial geographic variation in
the global burden of CKD attributable to air pollution
(figure 4), where low-income and lower middle-income
countries are most affected (figures 6 and 7). Air pollution is a significant global problem with well documented
transboundary health impacts due to international trade
and atmospheric pollutant transport45; it results in an estimated 4.2 million deaths per year and is worsening especially in low-income and middle-income countries.15 31 37 46
This is consistent with findings from the State of Global Air
2017 report where the largest increases in air pollution-related death were in rapidly industrialising low-income and
middle-income countries.31 37 The global burden of CKD

Figure 6 Plot showing burden of CKD attributable to PM2.5 in 194 countries and territories. Heat map tracks show percentiles,
which from inside to outside represent the YLL, YLD, ABD, effective difference and DALY. Scatter plot represents the DALYs (in
open circles) and effective difference (in closed circles) percentile, with a reference line at the median. Values are graded, from
low to high, as blue to red (on the Brewer palette). Countries are represented by their three-character country code. Regions
are ordered from low to high burden clockwise. ABD, attributable burden of disease; DALY, disability-adjusted life-years; DIFF,
effective difference; CKD, chronic kidney disease; NA, North America; PM2.5, fine particulate matter <2.5 µm; YLD, years living
with disability; YLL, years of life lost.
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much earlier loss of life attributable to air pollution-related kidney disease (figures 2 and 3). The results suggest
that as countries journey forward along the path of the
epidemiological transition, the contribution of air pollution to non-communicable disease mortality in general,
and more specifically CKD, becomes more pronounced.
Unfortunately, CKD has been largely ignored in the global
and WHO discussion of non-communicable diseases33–36;
CKD and its environmental drivers should feature on the
national, international development, and global health
agendas36–38 and should be assigned a priority commensurate with its ascending rank among the global burden
of diseases.2 10 13–16 39–44
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is increasing and its rank as a contributor to disability
and death is ascending43; it disproportionately impacts
low-income and middle-income countries,1 36 43 47 which
are least equipped to provide costly but life-saving CKD
care.33 34 While diabetes mellitus and hypertension are
the leading causes of CKD in high and upper middle-income countries, a significant proportion of CKD cannot
be explained by these traditional causes in low and lower
middle-income countries where environmental exposures loom prominently as potential drivers of non-communicable diseases including CKD.36 37 48–50 In an elegant
recent editorial, Jha and Modi51 reflected on the rise of
kidney failure death in India and suggested that a sizeable
portion of kidney failure is not due to traditional drivers
(diabetes mellitus) and advocated for a research agenda
to identify the drivers of this increased incidence of
kidney failure and kidney failure death. Others have also
advocated for greater understanding and larger emphasis
of the role of environmental air pollution in non-communicable diseases and specifically kidney disease.37 49 The
rise of CKD of unknown origin in Mesoamerica and other
geographies including India and Sri Lanka illustrates the
need for a broader and more comprehensive evaluation
of potential risk factors for development and progression
of kidney disease.36 52
Our frontier analysis provides a blueprint to comparatively evaluate the CKD DALYs attributable to air pollution
in countries with similar resources. The analysis identifies
a cluster of countries with substantially higher CKD DALYs
than would be expected for their place on the development
spectrum. The clustering of countries including Mesoamerican countries with a high CKD DALYs gap attributable
to air pollution is likely not random and (A) supports the
prescient hypothesis put forth by Orantes-Navarro et al52 for
inclusion of environmental air pollution—among others—
as a potential risk factor for CKD of unknown cause—a so far
elusive disease entity, vibrantly discussed among luminaries
in the field36 42 53–62— and (B) potentially represents unrealised opportunity for improved performance through interventions in the form of laws, health and economic policy
measures, reprioritisation and alignment of resources, technological transition and other devices that would ultimately
Bowe B, et al. BMJ Open 2019;9:e022450. doi:10.1136/bmjopen-2018-022450
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Figure 7 Age-standardised CKD DALYs (per
100 000) attributable to PM2.5 by World Bank income
classification. CKD, chronic kidney disease; DALY, disabilityadjusted life-years; PM2.5, fine particulate matter <2.5 µm.

close the DALYs gap. Similarly, our analysis identifies exemplar countries where performance for the county’s level of
development is considered leading (at the frontier pushing
the envelope), the identification of these exemplars provides
a window for better understanding of the potential drivers
for success34 and determination whether advocacy and wider
adoption of these drivers by other countries might yield
decreased CKD burden.38
While our analyses described the global and national
burden of kidney disease attributable to PM2.5 air pollution, consideration of the impact of other air pollutants (ie, nitrogen oxides, ozone, carbon monoxide,
PM10 and others),48 a higher spatial resolution analysis
at the subnational level and a greater understanding of
temporal trends over the years (eg, an annual global CKD
burden report that would track the contributions of all
risk factors over time) are certainly needed to develop a
better understanding of the epidemiology of CKD driven
by air pollution. Future work should revisit this question
to provide updated estimates of the burden of CKD attributable to ambient air pollution when updated and more
accurate estimates for PM2.5 and CKD are available across
the PM2.5 exposure spectrum for incorporation in integrative meta-regression methods.23 63 64
Three hypotheses have been proposed to explain the
mechanisms by which PM2.5 may play a role in the development of CKD: (A) Inhaled particular matter may result
in pulmonary inflammation, which could then lead to
systematic inflammation, (B) pollutants may also induce
disturbances in respiratory autonomic nervous system and
subsequently provoke systemic disturbances resulting in
kidney damage and (C) evidence has also suggested that
inhaled fine particulate matter when sufficiently small may
enter the bloodstream and subsequently interact with kidney
tissue.65 66 Furthermore, the association between PM2.5 and
CKD has been supported by other work. In a recent study
of the US Medicare population by Bragg-Gresham et al, a
4 µg/m3 increase in levels of PM2.5 was associated with higher
prevalence of diagnosed CKD (prevalence ratio=1.03;
95% CI 1.02 to 1.05).67 In a study of 100 629 adult non-CKD
Taiwanese residents by Chan et al, a 10 µg/m3 increase in
PM2.5 was associated with an increased risk of incident CKD
(HR: 1.06; 95% CI 1.02 to 1.10).68
This study has several limitations. Our analyses do
not account for the composition and toxic content of
PM2.5; however, studies have shown that estimates using
non-specific PM2.5 biomass alone will underestimate the
burden of kidney disease attributable to air pollution.7 8 46
Furthermore, we considered that risk plateaued for PM2.5
concentrations above 22 µg/m3; this likely yielded conservative estimate of the true burden of CKD attributable
to air pollution. Our estimates of CKD attributable to
PM2.5 at the global and national levels reflect the influence of PM2.5 levels across the globe and of demography
and underlying CKD rates. Our analyses were performed
at the global and national level where we assigned PM2.5
exposure and generated incident rates of CKD for every
country and territory; thus, our analyses do not provide
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